{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:41:43Z","timestamp":1792237303990,"version":"4.4.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Immune-mediated polyneuropathy (IMPN) manifests with generalised lower motor neuron (LMN) weakness and a remittent or relapsing clinical course. Evidence-based treatment recommendations for severely or chronically affected cats are limited. The objective of this study was to evaluate the clinical course and outcome of cats with IMPN after treatment with human intravenous immunoglobulins (hIVIg).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Medical records from two veterinary referral hospitals were reviewed (2018\u20132025) for cats with IMPN treated with hIVIg. Cats were treated with 1\u20132\u2009g\/kg hIVIg divided over 2\u20134 days (0.5\u2009g\/kg\/day). Clinical information, diagnostic findings, treatment details, and short- and long-term follow-up were evaluated retrospectively. Follow-up information was obtained from medical records and owner communication. Minimum follow-up duration was 8 months (range 8\u201351; median 17). Clinical course (partial and complete recovery, relapses) was compared between cats with acute\/recent onset (four cats) or chronic presentation (five cats).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of nine cats, eight exhibited clinical improvement after hIVIg administration, achieving ambulatory status (walking &gt;5 steps) within a median of 4 days (range 2\u20138). One cat failed to respond to hIVIg but improved after subsequent prednisolone therapy. For the overall cohort, the median time to complete recovery was 20 days, while the median time to partial recovery was 14 days. Relapses occurred in four cats, but weakness was less severe, and all cats recovered again. The remaining five cats remained relapse-free.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance:<\/jats:title>\n                    <jats:p>Human IVIg was well tolerated in this small cohort, and rapid clinical improvement was observed in most treated cats. These findings suggest that hIVIg may be considered as a treatment option in selected cats with IMPN, including those with acute and chronic presentations. Larger prospective studies, including comparison with no treatment or corticosteroids, are warranted to further assess its efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x261478277","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:19:18Z","timestamp":1785759558000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the clinical course of immune-mediated polyneuropathy in cats after treatment with human intravenous immunoglobulins"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3968-926X","authenticated-orcid":false,"given":"Annika Katharina","family":"Schmitz","sequence":"first","affiliation":[{"name":"Centre for Clinical Veterinary Medicine, Neurology Unit, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Paul","family":"Sablotni Aguilera","sequence":"additional","affiliation":[{"name":"Neurology Department, Small Animal Clinic Oberhaching, Oberhaching, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Buhmann","sequence":"additional","affiliation":[{"name":"AniCura Tierklinik Haar GmbH, Neurology Department, Haar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"van Renen","sequence":"additional","affiliation":[{"name":"Centre for Clinical Veterinary Medicine, Neurology Unit, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2154-5993","authenticated-orcid":false,"given":"Birgit","family":"Parzefall","sequence":"additional","affiliation":[{"name":"Neurology Department, Small Animal Clinic Oberhaching, Oberhaching, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-3280","authenticated-orcid":false,"given":"Kaspar","family":"Matiasek","sequence":"additional","affiliation":[{"name":"Section of Clinical and Comparative Neuropathology, Centre for Clinical Veterinary Medicine, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-7707","authenticated-orcid":false,"given":"Lara Alexa","family":"Matiasek","sequence":"additional","affiliation":[{"name":"Centre for Clinical Veterinary Medicine, Neurology Unit, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-1947","authenticated-orcid":false,"given":"Andrea","family":"Fischer","sequence":"additional","affiliation":[{"name":"Centre for Clinical Veterinary Medicine, Neurology Unit, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"van Renen J Fischer A Kolb N et al. Clinical course and diagnostic findings of biopsy controlled presumed immune-mediated polyneuropathy in 70 European cats. Front Vet Sci 2022; 9. https:\/\/doi.org\/10.3389\/fvets.2022.875657","DOI":"10.3389\/fvets.2022.875657"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Van Caenegem N Arti L Troupel T et al. Immune-mediated polyneuropathy in cats: Clinical description electrodiagnostic assessment and treatment. J Vet Intern Med 2023; 37: 1088\u20131099. https:\/\/doi.org\/10.1111\/jvim.16701","DOI":"10.1111\/jvim.16701"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Halstead SK Jackson M Bianchi E et al. Serum anti-GM2 and anti-GalNAc-GD1a ganglioside IgG antibodies are biomarkers for immune-mediated polyneuropathies in cats. J Peripher Nerv Syst 2023; 28: 32\u201340. https:\/\/doi.org\/10.1111\/jns.12529","DOI":"10.1111\/jns.12529"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Willison HJ Jacobs BC van Doorn PA. Guillain-Barr\u00e9 syndrome. Lancet 2016; 388: 717\u2013727. https:\/\/doi.org\/10.1016\/S0140-6736(16)00339-1","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Leonhard SE Mandarakas MR Gondim FAA et al. Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps. Nat Rev Neurol 2019; 15: 671\u2013683. https:\/\/doi.org\/10.1038\/s41582-019-0250-9","DOI":"10.1038\/s41582-019-0250-9"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Dimachkie MM Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2013; 15: 350\u2013366. https:\/\/doi.org\/10.1007\/s11940-013-0229-6","DOI":"10.1007\/s11940-013-0229-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez Y Vatti N Ram\u00edrez-Santana C et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun 2019; 102: 8\u201337. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.021","DOI":"10.1016\/j.jaut.2019.04.021"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Hattori N Misu K Koike H et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184: 57\u201363. https:\/\/doi.org\/10.1016\/s0022-510x(00)00493-7","DOI":"10.1016\/S0022-510X(00)00493-7"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Rajabally YA Min YG Nazeer KK et al. Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort. Eur J Neurol 2024; 31. https:\/\/doi.org\/10.1111\/ene.16399","DOI":"10.1111\/ene.16399"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"Pegat A Boisseau W Maisonobe T et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics electrophysiological study and response to treatment. J Peripher Nerv Syst 2020; 162\u2013170. https:\/\/doi.org\/10.1111\/jns.12380","DOI":"10.1111\/jns.12380"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Halstead SK Gourlay DS Penderis J et al. Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis. J Small Anim Pract 2022; 63: 104\u2013112. https:\/\/doi.org\/10.1111\/jsap.13439","DOI":"10.1111\/jsap.13439"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Rupp A Galban-Horcajo F Bianchi E et al. Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis. J Peripher Nerv Syst 2013; 18: 75\u201388. https:\/\/doi.org\/10.1111\/jns5.12011","DOI":"10.1111\/jns5.12011"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Hirschvogel K Jurina K Steinberg T. Clinical course of acute canine polyradiculoneuritis following treatment with human IV immunoglobulin. J Am Anim Hosp Assoc 2012; 48: 299\u2013309. https:\/\/doi.org\/10.5326\/JAAHA-MS-5651","DOI":"10.5326\/JAAHA-MS-5651"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Ruts L Drenthen J Jacobs BC et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barr\u00e9 syndrome: A prospective study. Neurology 2010; 74: 1680\u20131686. https:\/\/doi.org\/10.1212\/WNL.0b013e3181e07d14","DOI":"10.1212\/WNL.0b013e3181e07d14"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Stein MR Nelson RP Church JA et al. Safety and efficacy of Privigen\u00ae a novel 10% liquid immunoglobulin preparation for intravenous use in patients with primary immunodeficiencies. J Clin Immunol 2009; 29: 137\u2013144. https:\/\/doi.org\/10.1007\/s10875-008-9231-2","DOI":"10.1007\/s10875-008-9231-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Van den Bergh PYK van Doorn PA Hadden RDM et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force \u2013 second revision. Eur J Neurol 2021; 28: 3556\u20133583. https:\/\/doi.org\/10.1111\/ene.14959","DOI":"10.1111\/ene.14959"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"van Doorn PA Van den Bergh PYK Hadden RDM et al. European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain\u2013Barr\u00e9 syndrome. J Peripher Nerv Syst 2023; 28: 535\u2013563. https:\/\/doi.org\/10.1111\/jns.12594","DOI":"10.1111\/jns.12594"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Kane BK Greer RM. Human intravenous immunoglobulin use for hematological immune-mediated disease in dogs. J Am Vet Med Assoc 2023; 261: 1004\u20131010. https:\/\/doi.org\/10.2460\/javma.23.01.0043","DOI":"10.2460\/javma.23.01.0043"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","unstructured":"Baptista LFM Kelly D. Use of human intravenous immunoglobulin for treatment of immune-mediated haemolytic anaemia in two cats. Vet Rec Case Rep 2022; 10. https:\/\/doi.org\/10.1002\/vrc2.284","DOI":"10.1002\/vrc2.284"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"LeVine DN Goggs R Kohn B et al. ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats. J Vet Intern Med 2024; 38: 1982\u20132007. https:\/\/doi.org\/10.1111\/jvim.17079","DOI":"10.1111\/jvim.17079"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Whitley N. Dealing with immune-mediated haematological diseases in dogs and cats 1. Haemolytic anaemia. In Pract 2019; 41: 468\u2013477. https:\/\/doi.org\/10.1136\/inp.l6457","DOI":"10.1136\/inp.l6457"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","unstructured":"Byrne KP Giger U. Use of human immunoglobulin for treatment of severe erythema multiforme in a cat. JAVMA 2002; 220: 197\u2013201. https:\/\/doi.org\/10.2460\/javma.2002.220.197","DOI":"10.2460\/javma.2002.220.197"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Mizisin AP Shelton GD Burgers ML et al. Neurological complications associated with spontaneously occurring feline diabetes mellitus. J Neuropathol Exp Neurol 2002; 61: 872\u2013884. https:\/\/doi.org\/10.1093\/jnen\/61.10.872","DOI":"10.1093\/jnen\/61.10.872"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","unstructured":"Kolb N Matiasek K van Renen J et al. Biopsy characteristics subtypes and prognostic features in 107 cases of feline presumed immune-mediated polyneuropathy. Front Vet Sci 2022; 9. https:\/\/doi.org\/10.3389\/fvets.2022.928309","DOI":"10.3389\/fvets.2022.928309"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","unstructured":"Gross S Fischer A Rosati M et al. Nodo-paranodopathy internodopathy and cleftopathy: Target-based reclassification of Guillain\u2013Barr\u00e9-like immune-mediated polyradiculoneuropathies in dogs and cats. Neuromuscul Disord 2016; 26: 825\u2013836. https:\/\/doi.org\/10.1016\/j.nmd.2016.08.015","DOI":"10.1016\/j.nmd.2016.08.015"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","unstructured":"Aleman M Dickinson PJ Williams DC et al. Electrophysiologic confirmation of heterogenous motor polyneuropathy in young cats. J Vet Intern Med 2014; 28: 1789\u20131798. https:\/\/doi.org\/10.1111\/jvim.12439","DOI":"10.1111\/jvim.12439"},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","unstructured":"van Doorn PA Sommer C Rajabally YA. Autoimmune neuropathies: New guidelines and expert insights into clinical decision making. J Neurol Sci 2025; 479. https:\/\/doi.org\/10.1016\/j.jns.2025.125659","DOI":"10.1016\/j.jns.2025.125659"},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","unstructured":"Perricone C Triggianese P Bursi R et al. Intravenous immunoglobulins at the crossroad of autoimmunity and viral infections. Microorganisms 2021; 9. https:\/\/doi.org\/10.3390\/microorganisms9010121","DOI":"10.3390\/microorganisms9010121"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Update on intravenous immunoglobulin in neurology: Modulating neuro-autoimmunity evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics 2021; 18: 2397\u20132418. https:\/\/doi.org\/10.1007\/s13311-021-01108-4","DOI":"10.1007\/s13311-021-01108-4"},{"key":"e_1_3_3_31_2","first-page":"1279","article-title":"Acute idiopathic polyneuritis with spontaneous remission in an Abyssinian cat.","volume":"56","author":"Jeandel A","year":"2015","unstructured":"Jeandel A, Matiasek K, Blot S. Acute idiopathic polyneuritis with spontaneous remission in an Abyssinian cat. Can Vet J 2015; 56: 1279\u20131282.","journal-title":"Can Vet J"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","unstructured":"Malik R France M Churcher R et al. Prednisolone-responsive neuropathy in a cat. J Small Anim Pract 1991; 32: 529\u2013532. https:\/\/doi.org\/10.1111\/j.1748-5827.1991.tb00875.x","DOI":"10.1111\/j.1748-5827.1991.tb00875.x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","unstructured":"Guo Y Tian X Wang X et al. Adverse effects of immunoglobulin therapy. Front Immunol 2018; 9. https:\/\/doi.org\/10.3389\/fimmu.2018.01299","DOI":"10.3389\/fimmu.2018.01299"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","unstructured":"Koo Y Yun T Chae Y et al. Suspected human intravenous immunoglobulin-induced acute haemolytic anaemia in a dog. J Small Anim Pract 2022; 63: 482\u2013485. https:\/\/doi.org\/10.1111\/jsap.13449","DOI":"10.1111\/jsap.13449"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X261478277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X261478277","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X261478277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:00:24Z","timestamp":1792234824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X261478277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/1098612X261478277"],"URL":"https:\/\/doi.org\/10.1177\/1098612x261478277","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1098612X261478277"}}